Trial document



drksid header

  DRKS00003300

Trial Description

start of 1:1-Block title

Title

Correlation of subjective pain perception (VAS) and contact heat evoked potentials (CHEP) under remifentanil induced analgesia - with concomitant rating of vigilance by auditory evoked potentials (AEP) and OAA/S-score and analysis of synergistic drug effects on CHEP during propofol-induced loss of consciousness

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

[---]*

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Patients' safety during general anesthesia is warranted by numerous monitoring equipment. While the alert patient can express his pain in a detailed manner, pain can only be assessed by indirect parameters as increasing heart rate or blood pressure for the anesthetized patient. These indirect parameters do not change before pain exists. The registration of cerebral electrical activity and its changes by pain (pain evoked potentials) could serve as a method to measure analgesia during general anesthesia. The aim of this study is to design a parameter which detects analgesia objectively and directly during general anesthesia. This would offer an optimum analgesia during general anesthesia. Therefore contact heat will be generated at the skin and pain perception and pain evoked potentials will be recorded, first without drug application and then under analgesic drug. Concomitantly, the state of vigilance will be detected by the reaction of cerebral electrical activity after acoustic stimuli (auditory evoked potentials) and a clinically established score (observer’s assessment of alertness/sedation). Finally, auditory and pain evoked potentials will be recorded under analgesia during loss of consciousness. A correlation between changes of pain perception and changes of pain evoked potentials under analgesia is expected. Potentially sedative drug effects will be detected by auditory evoked potentials. It will be tested if pain evoked potentials serve as an objective and direct parameter of pain reduction even under loss of consciousness and general anesthesia. The study will be conducted before elective general anesthesia in the operating room, healthy patients are required.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

The basic aim of the study is to investigate the qualification of contact heat evoked potentials (CHEP) as an objective parameter of the analgesic component of general anesthesia. Therefore the analgesic effect of remifentanil after contact heat pain will be assessed via visual analog scale (VAS) and CHEP amplitudes. It has to be shown that CHEP reflect the reduction of pain under remifentanil. The correlation between remifentanil-induced changes of CHEP amplitudes and VAS will affirm the ability of CHEP to reflect analgesic effects objectively, provided that the reduction of pain is caused solely by analgesic effects. Potentially sedative drug effects will be detected by auditory evoked potentials (AEP) and OAA/S-score (observer's assessment of alertness/sedation). The correlation between CHEP amplitudes and VAS-changes under remifentanil will be compared to a baseline measurement without drug application and for verification of the results four different concentrations of remifentanil will be tested. Furthermore, CHEP will be recorded under loss of consciousness consistent with the conditions of general anesthesia. Therefore, propofol will be applied in addition to the group-specific remifentanil concentration.

end of 1:1-Block scientific synopsis
start of 1:1-Block forwarded Data

Do you plan to share individual participant data with other researchers?

[---]*

end of 1:1-Block forwarded Data
start of 1:1-Block forwarded Data Content

Description IPD sharing plan:

[---]*

end of 1:1-Block forwarded Data Content
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00003300
  •   2011/10/24
  •   [---]*
  •   yes
  •   Approved
  •   62/2010, Ethik-Kommission der Universität Witten/Herdecke
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  • [---]*
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   pain during anesthesia
  •   R52.9 -  Pain, unspecified
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   measurements without drug application about 30 minutes; after that measurements under 0,05 µg/kg/min remifentanil-infusion (i.v., continuously) about 40 minutes; in the course of the trail additional propofol-infusion until loss of consciousness (defined when volunteers stop squeezing the investigator's hand although requested); occurs shortly after propofol-induction and persists by continuous i.v. propofol-infusion; duration of combined remifentail/propofol-infusion about 30 minutes
  •   measurements without drug application about 30 minutes; after that measurements under 0,10 µg/kg/min remifentanil-infusion (i.v., continuously) about 40 minutes; in the course of the trail additional propofol-infusion until loss of consciousness (defined when volunteers stop squeezing the investigator's hand although requested); occurs shortly after propofol-induction and persists by continuous i.v. propofol-infusion; duration of combined remifentail/propofol-infusion about 30 minutes
  •   measurements without drug application about 30 minutes; after that measurements under 0,20 µg/kg/min remifentanil-infusion (i.v., continuously) about 40 minutes; in the course of the trail additional propofol-infusion until loss of consciousness (defined when volunteers stop squeezing the investigator's hand although requested); occurs shortly after propofol-induction and persists by continuous i.v. propofol-infusion; duration of combined remifentail/propofol-infusion about 30 minutes
  •   measurements without drug application about 30 minutes; after that measurements under 0,40 µg/kg/min remifentanil-infusion (i.v., continuously) about 40 minutes; in the course of the trail additional propofol-infusion until loss of consciousness (defined when volunteers stop squeezing the investigator's hand although requested); occurs shortly after propofol-induction and persists by continuous i.v. propofol-infusion; duration of combined remifentail/propofol-infusion about 30 minutes
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Blinded
  •   [---]*
  •   Active control
  •   Basic research/physiological study
  •   Parallel
  •   N/A
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

correlation between individual pain perception (described by visual analogue scale, VAS) and CHEP-amplitudes (Contact Heat Evoked Potentials) as the electroencephalographic correlate of the applied heat pain under remifentanil als analgesic. Remifentanil-induced changes of VAS and CHEP will be compared to the baseline measurement without drug application and will be analyzed under four different remifentanil-concentrations.

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

- correlation between remifentanil concentration and reduction of CHEP (Contact Heat Evoked Potential)-amplitudes
- registration of potential sedative effects of remifentanil by AEP (auditory evoked potentials) and OAA/S-score (Observer's Assessment of Alertness/Sedation-score)
- effects of loss of consciousness on CHEP (Contact Heat Evoked Potential)
- gender-related differences on CHEP (Contact Heat Evoked Potential)

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2013/01/31
  •   120
  •   Monocenter trial
  •   National
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   50   Years
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

ASA physical status 1-2 (classification system to assess fitness of patients before surgery): correlates with healthy patients (ASA 1) and patients with mild systemic disease (ASA 2), written consent, mental capacity, age: 18-50 years

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

cardiac, hepatic, renal, pulmonary or gastrointestinal diseases, disorders of gastrointestinal motility, psychiatric and neurologic diseases, altered cerebral perfusion, chronic intake of drugs, psychotropics or other substances with central- or peripheral nervous effects, hypacusis and deafness, analgetic long-term medication, chronic pain, agitated or anxious patients, allergy, known intolerance and contraindications against the used drugs, pregnancy

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Zentrum für Anästhesiologie, Helios Klinikum Wuppertal, Universität Witten/Herdecke
    • Mr.  Prof. Dr.  Gerhard  Schneider 
    • Heusnerstraße 40
    • 42283  Wuppertal
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Zentrum für Anästhesiologie, Helios Klinikum Wuppertal, Universität Witten/Herdecke
    • Ms.  Dr.  Gisela  Untergehrer 
    • Heusnerstraße 40
    • 42283  Wuppertal
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Zentrum für Anästhesiologie, Helios Klinikum Wuppertal, Universität Witten/Herdecke
    • Ms.  Dr.  Gisela  Untergehrer 
    • Heusnerstraße 40
    • 42283  Wuppertal
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Zentrum für Anästhesiologie, Helios Klinikum Wuppertal, Universität Witten/Herdecke
    • Heusnerstraße 40
    • 42283  Wuppertal
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
  • start of 1:1-Block address otherSupport
    • Deutsche Forschungsgemeinschaft
    • Kennedyallee 40
    • 53175  Bonn
    • Germany
    end of 1:1-Block address otherSupport
    start of 1:1-Block address contact otherSupport
    end of 1:1-Block address contact otherSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  • [---]*
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.